Clinical TrialTreatment-Resistant Depression (TRD)PsilocybinPlaceboPsilocybinRecruiting

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) (SYNVEST)

This Phase II interventional trial (n=12) will evaluate the effects of psilocybin (25 mg) with and without risperidone (1 mg) on synaptic density in adults with treatment-resistant depression (TRD).

Target Enrollment
12 participants
Study Type
Phase II interventional
Design
Non-randomized

Detailed Description

This non-randomised, sequential, Phase II trial will assess whether a single oral dose of psilocybin 25 mg, given with or without risperidone 1 mg, is associated with changes in synaptic density measured by an SV2A PET radiotracer in adults with treatment-resistant depression.

Participants receive supportive therapy; imaging feasibility, safety, and associations between PET SV2A measures and antidepressant response are primary aims. Two experimental arms compare psilocybin alone versus risperidone pre-treatment plus psilocybin; masking is open-label (none).

Study Protocol

Preparation

sessions

Dosing

1 sessions

Integration

sessions

Therapeutic Protocol

support

Study Arms & Interventions

Psilocybin + risperidone

experimental

Risperidone 1 mg given 60 minutes before psilocybin 25 mg; single administration with supportive therapy and PET imaging.

Interventions

  • Psilocybin25 mg
    via Oral• single dose• 1 doses total
  • Placebo
    via Oral• single dose• 1 doses total

    Risperidone 1 mg given 60 minutes before psilocybin; recorded as active concomitant drug

Psilocybin only

experimental

Single oral dose of psilocybin 25 mg with supportive therapy and PET imaging.

Interventions

  • Psilocybin25 mg
    via Oral• single dose• 1 doses total

Participants

Ages
18 – 65
Sexes
Male & Female

Inclusion Criteria

  • 1. Adults 18 to 65 years old;
  • 2. Must be deemed to have capacity to provide informed consent;
  • 3. Must sign and date the informed consent form;
  • 4. Stated willingness to comply with all study procedures;
  • 5. Ability to read and communicate in English, such that their literacy and comprehension is sufficient for understanding the consent form and study questionnaires, as evaluated by study staff obtaining consent;
  • 6. Primary DSM-5 diagnosis of non-psychotic MDD, single or recurrent, based on the Structured Clinical Interview for DSM-5 (SCID-5) administered at the first screening visit;
  • 7. Participants diagnosed with treatment-resistant depression defined as individuals with a baseline HamD-17 score > 14 and that have not responded to two or more separate trials of antidepressants at an adequate dosage and duration (an antidepressant resistance rating score of three or more is considered an adequate trial) based on the Antidepressant Treatment History Form (ATHF); there is no upper limit on the number of treatment failures;
  • 8. Ability to take oral medication;
  • 9. Individuals who are capable of becoming pregnant: use of highly effective contraception for at least 3 months prior to screening and agreement to use such a method during study participation;
  • 10. Individuals who are willing to taper off current antidepressant and antipsychotic medications for a minimum of 2-weeks (or more depending on the medication) prior to Baseline (V2) and whose physician confirms that it is safe for them to do so; and
  • 11. Agreement to adhere to Lifestyle Considerations (section 4.5) throughout study duration.

Exclusion Criteria

  • 1. Pregnant as assessed by a urine pregnancy test at Screening (V1) or individual's that intend to become pregnant during the study or are breastfeeding;
  • 2. Treatment with another investigational drug or other intervention within 30 days of Screening (V1);
  • 3. Have initiated psychotherapy in the preceding 12 weeks prior to Screening (V1);
  • 4. Have a DSM-5 diagnosis of substance use disorder (use of tobacco is permitted) within the preceding 6 months;
  • 5. Have active suicidal ideation with intent and plan as determined by item 3 of the HamD-17;
  • 6. Any DSM-5 lifetime diagnosis of a schizophrenia-spectrum disorder; obsessive-compulsive disorder, psychotic disorder (unless substance induced or due to a medical condition), bipolar I or II disorder, paranoid personality disorder, borderline personality disorder, or neurocognitive disorder as determined by medical history and the SCID-5 clinical interview;
  • 7. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I disorder as determined by the family medical history form and discussions with the participant;
  • 8. Presence of a relative or absolute contraindication to psilocybin, including a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
  • 9. Presence of baseline prolonged QTc or Torsade de Pointes as measured by the ECG or a history of long QTc syndrome or related risk factors;
  • 10. History of allergy or contraindication to risperidone
  • 11. Current or past traumatic brain injury or other neurological/neurodegenerative disorder
  • 12. Unable or unwilling to undergo PET or MRI scanning (e.g. claustrophobia, pacemaker);
  • 13. Blood disorders, disorders of coagulation, or ongoing use of anticoagulant medication
  • 14. Any disability that may prevent the participant from completing study requirements (e.g., non-correctable clinically significant sensory impairment such as not hearing well enough to communicate with study personnel during scans, or physical disability that does not allow them to lie still on the scanner bed for 1-2 hours);
  • 15. Participant exceeds the annual or lifetime amount of radiation
  • 16. Any other clinically significant physical illness including chronic infectious diseases or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.

Study Details

Locations

Centre for Addiction and Mental Health — Toronto, Ontario, Canada

Your Library